Last week, I was in Bio Spring Europe and I met Alain Vicari, Calypso Biotech’s CEO:
What is Calypso Biotech?
Calypso Biotech discovers and develops antibody therapies for indications in gastro-intestinal diseases. The company tackles on niche diseases, with therapeutic antibodies against difficult targets. Calypso was founded in Geneva, in 2013, as a spin-off of Merck-Serono.
The portfolio includes two preclinical programs. The first is for fistulizing Crohn’s disease in which current treatments available are still not very useful, including biologics. The second is for refractory celiac disease, an ultra-rare life-threatening condition, with no competitors on the market. Calypso Biotech will address clear unmet needs for patients suffering from these diseases.
Calypso Biotech was funded with €2,5M by MS-Ventures, the Merck Serono corporate venture arm. The startup is well supported by a scientific board of clinicians specialized in digestive diseases like Brian Feagan, one of the best gastroenterologist physician. Merck board of directors is also here to support Calypso, including Ipsen’s SVP Global Clinical Development Alex LeBeaut as independent director.